Ophthalmic medical company Glaukos Corporation (NYSE:GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant.
- The data showed sustained and substantial reductions in intraocular pressure (IOP) in a 36-month analysis.
- The iDose TR contains formulated travoprost, a prostaglandin analog to reduce IOP.
- 70% and 68% of subjects in the fast- and slow-release iDose TR arms, respectively, were well-controlled with the same or fewer IOP-lowering topical medications at 36 months versus screening, versus 46% of subjects in the timolol control arm.
- Average IOP reductions from baseline observed at 36 months were 8.3 mmHg and 8.5 mmHg in the fast- and slow-release iDose TR arms, respectively, versus 8.2 mmHg in the timolol control arm.
- Overall, iDose TR subjects performed similarly to timolol subjects at 36 months in terms of mean IOP reductions with fewer topical medications versus timolol.
- In June last year, Glaukos completed patient enrollment and randomization in its ongoing Phase 3 clinical program for iDose TR.
- The 12-month Phase 3 trial results are expected to support Glaukos' targeted NDA submission in 2022 and FDA approval for iDose TR in 2023.
- Price Action: GKOS shares closed 10.62% higher at $53.34 during after-hours trading on Tuesday.
